

**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2014**

Rs. In Lacs

| Particulars   | Quarter        | Quarter        | For the         | For the         |
|---|----------------|----------------|-----------------|-----------------|
|   | Ended          | Ended          | Year Ended      | Year Ended      |
|   | 30.06.2014     | 30.06.2013     | 31.03.2014      | 31.03.2013      |
|   | Unaudited      | Unaudited      | Audited         | Audited         |
| <b>INCOME:</b>  |                |                |                 |                 |
| Net Sales / Income from Operations (Net of Excise Duty)                                 | 3908.05        | 2536.92        | 12291.58        | 9998.31         |
| Other Operating Income  | 2.06           | 2.33           | 22.92           | 42.45           |
| <b>Total Income from Operations (Net)</b>   | <b>3910.11</b> | <b>2539.25</b> | <b>12314.50</b> | <b>10040.76</b> |
| <b>EXPENSES:</b>  |                |                |                 |                 |
| Cost of Materials Consumed  | 1646.95        | 951.59         | 5194.33         | 3287.68         |
| Purchase of Stock-in-Trade  | 553.44         | 294.46         | 1377.03         | 1921.99         |
| Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade           | (1.65)         | 83.25          | 40.87           | (107.75)        |
| Employee Benefits Expenses  | 367.53         | 144.05         | 1194.34         | 544.85          |
| Depreciation and Amortisation Expenses  | 99.24          | 63.00          | 246.77          | 217.95          |
| Other Expenses  | 949.89         | 779.37         | 3291.42         | 3278.98         |
| <b>Total Expenses</b>   | <b>3615.40</b> | <b>2315.72</b> | <b>11344.75</b> | <b>9143.70</b>  |
| <b>Profit from Operations before Other Income, finance costs and Exceptional Items</b>  | <b>294.70</b>  | <b>223.53</b>  | <b>969.75</b>   | <b>897.06</b>   |
| Other Income  | 29.24          | 1.12           | 49.15           | 12.25           |
| <b>Profit from ordinary activities before finance costs and exceptional items</b>       | <b>323.95</b>  | <b>224.65</b>  | <b>1018.90</b>  | <b>909.31</b>   |
| Finance Costs   | 105.85         | 102.08         | 391.57          | 383.00          |
| <b>Profit from ordinary activities after finance costs but before exceptional items</b> | <b>218.10</b>  | <b>122.57</b>  | <b>627.32</b>   | <b>526.31</b>   |
| Exceptional Items   | 0.00           | 0.00           | 0.00            | 0.00            |
| <b>Profit from Ordinary Activities Before Tax</b>                                       | <b>218.10</b>  | <b>122.57</b>  | <b>627.32</b>   | <b>526.31</b>   |
| Current Tax   | 75.00          | 43.00          | 151.00          | 149.50          |
| Deferred Tax  | 23.73          | 0.00           | 7.01            | 53.19           |
| Short/(Excess) Tax Provisions of Earlier Years  | 0.00           | 0.00           | 42.90           | (9.30)          |
| <b>Net Profit from Ordinary Activities After Tax</b>                                    | <b>119.37</b>  | <b>79.57</b>   | <b>426.41</b>   | <b>332.92</b>   |
| Extraordinary Items (Net of Tax Expenses)   | 0.00           | 0.00           | 0.00            | 0.00            |
| <b>Net Profit for the Period</b>  | <b>119.37</b>  | <b>79.57</b>   | <b>426.41</b>   | <b>332.92</b>   |
| Paid up Equity Share Capital (Face Value of Rs 1/- Each)                                | 773.50         | 773.50         | 773.50          | 773.50          |
| Reserves Excluding Revaluation Reserves   | 1966.72        | 1545.46        | 1847.35         | 1465.89         |
| <b>E.P.S</b>  | <b>0.15</b>    | <b>0.10</b>    | <b>0.55</b>     | <b>0.43</b>     |
| <b>Public Shareholding</b>  |                |                |                 |                 |
| -- Number of Shares of Rs 1/- Each  | 23222355       | 23222355       | 23222355        | 23222355        |
| -- Percentage of shareholding   | 30.02%         | 30.02%         | 30.02%          | 30.02%          |
| <b>Promoters and Promoter group Shareholding</b>  |                |                |                 |                 |
| <b>a) Pledged / Encumbered</b>  |                |                |                 |                 |
| -- Number of Shares of Rs 1/- Each  | 0              | 0              | 0               | 0               |
| -- Percentage of Shares the total Shareholding of Promoter and Promoter group           | 0.00%          | 0.00%          | 0.00%           | 0.00%           |
| -- Percentage of Shareholding on total Capital of the company                           | 0.00%          | 0.00%          | 0.00%           | 0.00%           |
| <b>b) Non - Encumbered</b>  |                |                |                 |                 |
| -- Number of Shares of Rs 1/- Each  | 54127645       | 54127645       | 54127645        | 54127645        |
| -- Percentage of Shares the total Shareholding of Promoter and Promoter group           | 100.00%        | 100.00%        | 100.00%         | 100.00%         |
| -- Percentage of Shareholding on total Capital of the company                           | 69.98%         | 69.98%         | 69.98%          | 69.98%          |





**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

| UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 30.06.2014 |                          |                          |                                 | Rs in Lacs                    |
|---|--------------------------|--------------------------|---------------------------------|-------------------------------|
| Particulars   | Quarter Ended 30.06.2014 | Quarter Ended 30.06.2013 | For the Period Ended 31.03.2014 | For the Year Ended 31.03.2013 |
|   | Unaudited                | Unaudited                | Audited                         | Audited                       |
| <b>SEGMENT REVENUE</b>  |                          |                          |                                 |                               |
| <b>Sales &amp; Service</b>                                      |                          |                          |                                 |                               |
| Pharma  | 3554.96                  | 2291.38                  | 11051.26                        | 9085.06                       |
| Consumer  | 353.09                   | 245.54                   | 1240.32                         | 913.25                        |
| <b>Total</b>  | <b>3908.05</b>           | <b>2536.92</b>           | <b>12291.58</b>                 | <b>9998.31</b>                |
| Unallocabel Income  | 31.30                    | 3.45                     | 72.07                           | 54.70                         |
| <b>Total Segment Revenue</b>                                    | <b>3939.35</b>           | <b>2540.37</b>           | <b>12363.65</b>                 | <b>10053.01</b>               |
| <b>SEGMENT RESULTS</b>  |                          |                          |                                 |                               |
| Pharma  | 693.20                   | 445.20                   | 2144.25                         | 1761.51                       |
| Consumer  | 37.30                    | 47.85                    | 238.83                          | 176.66                        |
| <b>TOTAL</b>  | <b>730.50</b>            | <b>493.05</b>            | <b>2383.08</b>                  | <b>1938.17</b>                |
| Less: Unallocated over heads                                    | 307.32                   | 205.40                   | 1117.41                         | 810.91                        |
| Finance Charges   | 105.85                   | 102.08                   | 391.57                          | 383.00                        |
| Depreciation  | 99.24                    | 63.00                    | 246.77                          | 217.95                        |
| Tax provision   | 98.73                    | 43.00                    | 200.91                          | 193.39                        |
| <b>Net Profit after Tax</b>                                     | <b>119.37</b>            | <b>79.57</b>             | <b>426.41</b>                   | <b>332.92</b>                 |

Notes forming part of the un-audited financial results for the quarter ended June 30, 2014

- The above interim financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors in their meetings held on August 14, 2014. The same has been subjected to limited review by the Statutory Auditors.
- For the preparation of these financial results, the company has followed the same accounting policies and generally accepted practices adopted for the preparation of audited financial statements for the year ended March 31, 2014, except for accounting of depreciation on fixed assets.
- As per the requirement of the Companies Act, 2013 (Act), the company has reassessed the remaining useful life of the fixed assets taking into consideration the useful life prescribed in Schedule II of the Act. This has resulted in an additional charge of depreciation of Rs. 11.62 Lacs for the quarter ended June 30, 2014. Further, the written down value of the assets of Rs. 288.28 Lacs as on April 1, 2014 (net of deferred tax of Rs. 138.45 Lacs) whose residual life is exhausted has been adjusted against the opening balance of Reserves and Surplus.
- Disclosure about investor-complaints: Complaints at the beginning of the period Nil, Received during the period Nil; Disposed off during the period: Nil, Unresolved as on June 30, 2014: Nil.
- Corresponding previous period figures have been regrouped / rearranged wherever necessary to make them comparable with current period figures.
- The figures of the last quarter of financial year 2013 – 2014 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2014 and the unaudited published year – to – date figures upto December 31, 2013 which were subject to limited review.

By Order of the Board  
Gufic Biosciences Limited


  
Jayesh P. Choksi  
Chairman  
Mumbai dated August 14, 2014
